Abstract
Protein kinase B (PKB or Akt) is a central component of the PI3K – PKB – mTOR signalling cascade and is firmly established as an attractive target for pharmacological intervention in cancer. A number of small molecule inhibitors with well-defined, direct molecular interactions with PKB are now known, covering a range of mechanisms from ATP- or substrate-competitive inhibition, through allosteric modulation of the kinase activity, to inhibition of the phosphatidylinositol-dependent activation process. The development of small molecule inhibitors of PKB has benefited greatly from the application of structural biology techniques, particularly for lead generation and the optimisation of compound potency and selectivity. The development of the major chemical series of PKB inhibitors will be outlined, with an emphasis on the application of structure-based design and the strategies used to optimise compound pharmacodynamics, efficacy and therapeutic window. The development of small molecules targeting PKB for anticancer therapy has reached an exciting stage, with the first selective inhibitors entering clinical trials, and several additional chemotypes demonstrating efficacy in preclinical models.
Keywords: Protein kinase B, Akt, inhibitors, anticancer agents, structure-based design
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeted Small-Molecule Inhibitors of Protein Kinase B as Anticancer Agents
Volume: 9 Issue: 1
Author(s): Ian Collins
Affiliation:
Keywords: Protein kinase B, Akt, inhibitors, anticancer agents, structure-based design
Abstract: Protein kinase B (PKB or Akt) is a central component of the PI3K – PKB – mTOR signalling cascade and is firmly established as an attractive target for pharmacological intervention in cancer. A number of small molecule inhibitors with well-defined, direct molecular interactions with PKB are now known, covering a range of mechanisms from ATP- or substrate-competitive inhibition, through allosteric modulation of the kinase activity, to inhibition of the phosphatidylinositol-dependent activation process. The development of small molecule inhibitors of PKB has benefited greatly from the application of structural biology techniques, particularly for lead generation and the optimisation of compound potency and selectivity. The development of the major chemical series of PKB inhibitors will be outlined, with an emphasis on the application of structure-based design and the strategies used to optimise compound pharmacodynamics, efficacy and therapeutic window. The development of small molecules targeting PKB for anticancer therapy has reached an exciting stage, with the first selective inhibitors entering clinical trials, and several additional chemotypes demonstrating efficacy in preclinical models.
Export Options
About this article
Cite this article as:
Collins Ian, Targeted Small-Molecule Inhibitors of Protein Kinase B as Anticancer Agents, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (1) . https://dx.doi.org/10.2174/187152009787047734
DOI https://dx.doi.org/10.2174/187152009787047734 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editor-in-Chief
Current Cancer Drug Targets PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design Cell-penetrating Peptides as Nucleic Acid Delivery Systems: From Biophysics to Biological Applications
Current Pharmaceutical Design Redox Regulation and Cancer Therapy
Current Pharmaceutical Design Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Effective Strategies and Applications of Dendrimers in the Treatment of Ovarian Cancer
Current Pharmaceutical Design Using Xpert MTB/RIF
Current Respiratory Medicine Reviews Chemoprevention of Colorectal Cancer: Ready for Routine Use?
Current Topics in Medicinal Chemistry Targeting Tuberculosis: A Glimpse of Promising Drug Targets
Mini-Reviews in Medicinal Chemistry Chemical Characterization of Phytochemicals of Cucurbitaceae Family by Gas Chromatography – Mass Spectroscopy
Current Traditional Medicine Circulating Exosomes as Potential Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Signaling Molecules: The Pathogenic Role of the IL-6/STAT-3 Trans Signaling Pathway in Intestinal Inflammation and in Colonic Cancer
Current Drug Targets Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery B-Lymphocytes Govern the Pathogenesis of Sjogren's Syndrome
Current Pharmaceutical Biotechnology The Targets of Curcumin
Current Drug Targets Recent Advance of Computational Approaches in Genomics and Proteomics
Current Bioinformatics Fullerenes for Applications in Biology and Medicine
Current Medicinal Chemistry Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) P-Glycoprotein, but not Multidrug Resistance Protein 4, Plays a Role in the Systemic Clearance of Irinotecan and SN-38 in Mice
Drug Metabolism Letters The miRNAs and Epithelial-Mesenchymal Transition in Cancers
Current Pharmaceutical Design